2024 targets achieved; markets appreciated shareholder rewards
30/01/25 -"Even though Q4 results were somewhat behind the consensus, Sanofi slightly exceeded its 2024 guidance. The 2025 outlook was encouraging. Moreover, the investors welcomed the management’s ..."
Pages
74
Language
English
Published on
30/01/25
You may also be interested by these reports :
06/11/26
Genmab’s sales missed expectations, but profitability significantly exceeded expectations. Growth was driven by contributions from most offerings, ...
06/11/26
Sanofi’s growth in recent years has been single-handedly driven by its cornerstone immunology treatment Dupixent, though there has been some support ...
06/11/26
Novonesis delivered an in-line Q3 26, with revenue and adjusted EBITDA marginally ahead of consensus. Food & Beverages (F&B) accelerated to 14%, ...
05/11/26
The Q3 qualitative update did not materially change the full-year outlook, as Branded’s strong momentum made up for the relative weakness in ...